Muder R R, Brennen C, Goetz A M, Wagener M M, Rihs J D
Department of Medicine, Department of Veterans Affairs Medical Center, Pittsburgh, Pennsylvania 15240.
Antimicrob Agents Chemother. 1991 Feb;35(2):256-8. doi: 10.1128/AAC.35.2.256.
We performed a case-control study of risk factors for the acquisition of ciprofloxacin-resistant gram-negative isolates in a Veterans Affairs medical center. Sixty-five patients with resistant isolates and 50 control patients were identified. Prior fluoroquinolone use was significantly more frequent among patients with resistant isolates than it was among controls (58 versus 20%; P = 0.0001). The association with prior quinolone use was stronger in the long-term-care division (81 versus 32%; P = 0.0005) than it was in the acute-care division (29 versus 0%; P = 0.015). On multivariate analysis, prior receipt of a fluoroquinolone was the single most significant risk factor for isolation of a ciprofloxacin-resistant gram-negative organism (P = 0.0001).
我们在一家退伍军人事务医疗中心进行了一项关于获得耐环丙沙星革兰氏阴性菌分离株危险因素的病例对照研究。确定了65例有耐药分离株的患者和50例对照患者。有耐药分离株的患者中先前使用氟喹诺酮类药物的频率显著高于对照组(58%对20%;P = 0.0001)。与先前使用喹诺酮类药物的关联在长期护理部门(81%对32%;P = 0.0005)比在急性护理部门(29%对0%;P = 0.015)更强。多变量分析显示,先前接受氟喹诺酮类药物是分离出耐环丙沙星革兰氏阴性菌的唯一最重要危险因素(P = 0.0001)。